Yasui Naoko, Sekiguchi Kenji, Hamaguchi Hirotoshi, Kanda Fumio
Division of Neurology, Kobe University Hospital, Kobe 650-0017, Japan.
Kobe J Med Sci. 2011 Feb 2;56(5):E214-9.
Depression is a common occurrence in patients with Parkinson's disease (PD). Pramipexole is a dopamine agonist that has been used to treat both motor and non-motor symptoms associated with PD. We conducted a study to elucidate the effect of pramipexole on each of the depressive symptoms as assessed by the Zung Self-Rating Depression Scale (SDS). Twenty patients with PD were treated with pramipexole 1.5-3.0 mg daily for 2-3 months. The SDS and the Unified Parkinson Disease Rating Score (UPDRS) were measured in each subject before and after the treatment. Both the SDS and the UPDRS decreased significantly after treatment with pramipexole. Individual assessment of each item in the SDS indicated that "crying spell", "confusion", "psychomotor retardation", "emptiness", and "dissatisfaction" symptoms improved significantly following treatment, while "depressed affect", "decreased libido", "constipation", and "indecisiveness" symptoms were worse after the treatment. As the symptom of "indecisiveness" did not respond to treatment, it might be an essential symptom in patients with PD.
抑郁症在帕金森病（PD）患者中很常见。普拉克索是一种多巴胺激动剂，已被用于治疗与PD相关的运动和非运动症状。我们进行了一项研究，以阐明普拉克索对通过zung自评抑郁量表（SDS）评估的每种抑郁症状的影响。20名PD患者每天接受1.5 - 3.0毫克普拉克索治疗，持续2 - 3个月。在治疗前后对每个受试者测量SDS和统一帕金森病评定量表（UPDRS）。使用普拉克索治疗后，SDS和UPDRS均显著下降。对SDS中每个项目的个体评估表明，“哭泣发作”、“困惑”、“精神运动迟缓”、“空虚”和“不满”症状在治疗后显著改善，而“情绪低落”、“性欲减退”、“便秘”和“犹豫不决”症状在治疗后更严重。由于“犹豫不决”症状对治疗无反应，它可能是PD患者的一个基本症状。
